ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

XFOR vs IRLA // RSI-14 & 200D SMA MOMENTUM

X4 Pharmaceuticals Inc. (NASDAQ) VS. IRulya Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: XFOR 2 — IRLA 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: XFOR
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XFOR VS. IRLA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC XFOR IRLA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 83.60% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -12.19% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 1/9 +2.00 XFOR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 60.3 52.5 +7.80 XFOR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $333.1M $342.8M -$9.7M IRLA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR XFOR REV IRLA REV XFOR GROSS % IRLA GROSS % XFOR FCF IRLA FCF
FY 2025 $35.1M $0 83.6% — -$85.6M -$41.8M
FY 2024 $2.6M $0 68.8% — -$131.2M -$32.2M
FY 2023 $0 $0 — — -$96.5M -$18.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XFOR // BETA —
IRLA // BETA —